ELECTROPHILES AND ELECTROPHILE PRO-DRUGS AS RAD51 INHIBITORS
A method comprising co-administering to a subject having cancer, suspected of having cancer, or at risk of developing cancer:a therapeutically effective amount of at least one compound (a) selected from (a)(i) a nitroalkene fatty acid, (a)(ii) an unsaturated fatty acid having an electron withdrawing...
Saved in:
Main Authors | , , |
---|---|
Format | Patent |
Language | English French German |
Published |
17.08.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | A method comprising co-administering to a subject having cancer, suspected of having cancer, or at risk of developing cancer:a therapeutically effective amount of at least one compound (a) selected from (a)(i) a nitroalkene fatty acid, (a)(ii) an unsaturated fatty acid having an electron withdrawing group, a leaving group, and a carbon-carbon double bond disposed between the electron withdrawing group and the leaving group, (a)(iii) a thiolated nitro fatty acid, or (a)(iv) a dicarboxylic acid compound containing an electron withdrawing group; anda therapeutically effective amount of at least one anti-neoplastic agent (b),wherein the cancer is a cancer with hereditary etiology of defects in DNA repair genes, a cancer with a high rate of spontaneous genomic instability, a cancer that responds well to DNA damaging agent(s), or a cancer that responds well to a combination of DNA damaging agent(s) with immunotherapy. |
---|---|
Bibliography: | Application Number: EP20190885442 |